AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1628168 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoring system for skin involvement
Number of subjects: 12
Study 1628168 — intervention group
Group type: COMPARATOR
Intervention: Shaded manikin method for estimating skin involvement
Number of subjects: 12
Study 6421196 — intervention group
Group type: EXPERIMENTAL
Intervention: High nitrogen intake (15 mg nitrogen per kcal REE, approximately 21 g/day)
Number of subjects: 8
Study 6421196 — intervention group
Group type: COMPARATOR
Intervention: Low nitrogen intake (7.5 mg nitrogen per kcal REE, approximately 11 g/day)
Number of subjects: 8
Study 31062950 — intervention group
Group type: COMPARATOR
Intervention: HIIT (Group 1), four runs at maximal speed with 30 s active recovery (total: 48 runs)
Number of subjects: 34
Study 31062950 — intervention group
Group type: EXPERIMENTAL
Intervention: proHIIT (Group 2), 4 runs at maximal speed with 30 s active recovery with one extra repetition every week (up to seven runs, for a total of 66 runs)
Number of subjects: 34
Study 30169298 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Integrated Care (FICare)
Number of subjects: 1786
Study 30169298 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 1786
Study 27861670 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implant placement (test group)
Number of subjects: 40
Study 27861670 — intervention group
Group type: COMPARATOR
Intervention: Delayed implant placement (control group)
Number of subjects: 40
Study 25386678 — intervention group
Group type: EXPERIMENTAL
Intervention: Post discharge phone call
Number of subjects: 328
Study 22176154 — intervention group
Group type: EXPERIMENTAL
Intervention: FreeStyle Lite®
Number of subjects: 501
Study 22176154 — intervention group
Group type: EXPERIMENTAL
Intervention: FreeStyle Freedom Lite
Number of subjects: 501
Study 22176154 — intervention group
Group type: EXPERIMENTAL
Intervention: Accu‐Chek® Aviva
Number of subjects: 501
Study 22176154 — intervention group
Group type: COMPARATOR
Intervention: Contour®
Number of subjects: 501
Study 22176154 — intervention group
Group type: COMPARATOR
Intervention: OneTouch® UltraEasy®
Number of subjects: 501
Study 19344527 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rate (HDR) brachytherapy
Number of subjects: 2065
Study 17785979 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g chilli powder twice daily along with identical fiber and analgesics
Number of subjects: 56
Study 17785979 — intervention group
Group type: COMPARATOR
Intervention: Analgesics and fiber supplement alone
Number of subjects: 56
Study 14628149 — intervention group
Group type: EXPERIMENTAL
Intervention: IR laser treatment
Number of subjects: 46
Study 14628149 — intervention group
Group type: COMPARATOR
Intervention: Sham laser (control)
Number of subjects: 46
Study 12147561 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 42
Study 12147561 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 42
Study 12147561 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study 9818307 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-focused group psychotherapy (GFGP)
Number of subjects: 13
Study 9818307 — intervention group
Group type: COMPARATOR
Intervention: Reminiscence therapy (RT)
Number of subjects: 13
Study 8130021 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate (8 mmol loading dose over 5 minutes plus 65 mmol over 24 hours)
Number of subjects: 2316
Study 8130021 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 2316
Study 2673331 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate and cyclosporin (n = 22)
Number of subjects: 46
Study 2673331 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate alone (n = 24)
Number of subjects: 46
Study 2673331 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 46
Study 31212115 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-requiring diabetics (IRD)
Number of subjects: 798592
Study 31212115 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-insulin requiring diabetics (NIRD)
Number of subjects: 798592
Study 31212115 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation
Number of subjects: 798592
Study 28971636 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam (20 mg)
Number of subjects: 80
Study 28971636 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (1000 mg)
Number of subjects: 80
Study 25750093 — intervention group
Group type: EXPERIMENTAL
Intervention: Mud-bath therapy (MBT)
Number of subjects: 95
Study 25750093 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular care routine)
Number of subjects: 95
Study 23743715 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumventing obstacles instead of rotating shoulders when the aperture was too small for straight passage.
Number of subjects: 12
Study 23743715 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in travel path when approaching obstacles.
Number of subjects: 12
Study 23743715 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial-lateral center of mass variability during the approach to the obstacles.
Number of subjects: 12
Study 22115340 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based walking intervention
Number of subjects: 484
Study 22115340 — intervention group
Group type: COMPARATOR
Intervention: Health-education waiting list group (control)
Number of subjects: 484
Study 22115340 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical performance assessments (subset of participants, n = 194)
Number of subjects: 484
Study 19793849 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic index diet + Exercise (LoGI + EX)
Number of subjects: 32
Study 19793849 — intervention group
Group type: COMPARATOR
Intervention: High-glycemic index diet + Exercise (HiGI + EX)
Number of subjects: 32
Study 19793849 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (LoGI + EX and HiGI + EX)
Number of subjects: 32
Study 17101314 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (880 mug, divided twice daily for 3 months)
Number of subjects: 36
Study 17101314 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 36
Study 15568199 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational mode of processing
Number of subjects: 163
Study 15568199 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential mode of processing
Number of subjects: 163
Study 11329400 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (2-6 mg/day, mean modal dose=4.8 mg/day)
Number of subjects: 377
Study 11329400 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (5-20 mg/day, mean modal dose=12.4 mg/day)
Number of subjects: 377
Study 11329400 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 377
Study 11329400 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 377
Study 8970936 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine (8 microg per kilogram of birth weight) administered daily for six weeks
Number of subjects: 200
Study 8970936 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered daily for six weeks
Number of subjects: 200
Study 8970936 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine treatment
Number of subjects: 200
Study 8215267 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g every 24 h)
Number of subjects: 60
Study 8215267 — intervention group
Group type: COMPARATOR
Intervention: Cefonicid (2 g every 12 h)
Number of subjects: 60
Study 2442991 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (mean dose 94 mg daily) plus class I antiarrhythmic agents (quinidine or procainamide)
Number of subjects: 18
Study 2442991 — intervention group
Group type: COMPARATOR
Intervention: Class I antiarrhythmic agents alone
Number of subjects: 18
Study 29783983 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary support (seven sessions with a dietitian)
Number of subjects: 67
Study 29783983 — intervention group
Group type: COMPARATOR
Intervention: Social support (befriending) control condition
Number of subjects: 67
Study 27372221 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated healthcare model comprising an assigned internist and a hospital liaison nurse
Number of subjects: 140
Study 27372221 — intervention group
Group type: COMPARATOR
Intervention: Standard care (conventional reactive healthcare system)
Number of subjects: 140
Study 27372221 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup of patients under 80 years of age with three or more clinical categories
Number of subjects: 140
Study 25477988 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized herbal decoction
Number of subjects: 3
Study 25477988 — intervention group
Group type: COMPARATOR
Intervention: Control decoction
Number of subjects: 3
Study 22801400 — intervention group
Group type: EXPERIMENTAL
Intervention: Miller's original vein collar
Number of subjects: 180
Study 22801400 — intervention group
Group type: EXPERIMENTAL
Intervention: St Mary's boot vein collar
Number of subjects: 180
Study 22801400 — intervention group
Group type: EXPERIMENTAL
Intervention: Vein collar with length/height ratio between 1.18 and 1.63
Number of subjects: 180
Study 22801400 — intervention group
Group type: EXPERIMENTAL
Intervention: Large volume vein collar
Number of subjects: 180
Study 22801400 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger volume and length/height ratio between 1.18 and 1.63
Number of subjects: 180
Study 22801400 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger volume and length/height ratio > 1.63
Number of subjects: 180
Study 20039197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 20039197 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 163
Study 18772275 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified total-body recumbent stepper (mTBRS-XT)
Number of subjects: 11
Study 18772275 — intervention group
Group type: COMPARATOR
Intervention: Cycle ergometer exercise protocol
Number of subjects: 11
Study 15617667 — intervention group
Group type: EXPERIMENTAL
Intervention: EYES condition
Number of subjects: 0
Study 15617667 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR condition
Number of subjects: 0
Study 12171822 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI/DED (metered-dose inhaler with delivery enhancement device)
Number of subjects: 93
Study 12171822 — intervention group
Group type: COMPARATOR
Intervention: Wet nebulization (as a control for teaching)
Number of subjects: 93
Study 12171822 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI/DED teaching
Number of subjects: 93
Study 12171822 — intervention group
Group type: COMPARATOR
Intervention: Single bronchodilator dose by wet nebulization
Number of subjects: 93
Study 10483808 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric contractions training group (n = 12)
Number of subjects: 20
Study 10483808 — intervention group
Group type: COMPARATOR
Intervention: Untrained control group (n = 8)
Number of subjects: 20
Study 8583366 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous milrinone loading dose of 50 micrograms kg‐1 over 10 min followed by maintenance infusion of 0.45 micrograms kg‐1 min‐1 for moderate renal impairment (n = 10)
Number of subjects: 21
Study 8583366 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous milrinone loading dose of 50 micrograms kg‐1 over 10 min followed by maintenance infusion of 0.35 micrograms kg‐1 min‐1 for severe renal impairment (n = 11)
Number of subjects: 21
Study 8583366 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous milrinone (both groups)
Number of subjects: 21
Study 2111933 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prophylactic penicillin
Number of subjects: 0
Study 2111933 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 7030973 — intervention group
Group type: EXPERIMENTAL
Intervention: Dioxonium (30, 40, and 60 microgram/kg i.v.)
Number of subjects: 0
Study 7030973 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium (0.05 and 0.1 mg/kg i.v.)
Number of subjects: 0
Study 30855468 — intervention group
Group type: EXPERIMENTAL
Intervention: Supreme group (n=41)
Number of subjects: 84
Study 30855468 — intervention group
Group type: COMPARATOR
Intervention: Air-Q SP group (n=43)
Number of subjects: 84
Study 28062124 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message group (received two messages weekly for four consecutive weeks)
Number of subjects: 317
Study 28062124 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not receive text messages)
Number of subjects: 317
Study 27716184 — intervention group
Group type: EXPERIMENTAL
Intervention: FET-PET guided radiotherapy target volume delineation
Number of subjects: 200
Study 27716184 — intervention group
Group type: COMPARATOR
Intervention: T1Gd-MRI guided radiotherapy target volume delineation
Number of subjects: 200
Study 25726788 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptol (1000 mg daily for 30 days)
Number of subjects: 60
Study 25726788 — intervention group
Group type: EXPERIMENTAL
Intervention: Noofen (500 mg daily for 30 days)
Number of subjects: 60
Study 23082447 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline 0.5 mg weekly for 3 months
Number of subjects: 17
Study 23082447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 19572930 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg/ml ropivacaine
Number of subjects: 108
Study 19572930 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg/ml ropivacaine with 0.2 mcg/kg/h fentanyl
Number of subjects: 108
Study 19572930 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/ml ropivacaine
Number of subjects: 108
Study 19572930 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/ml ropivacaine with 0.2 mcg/kg/h fentanyl
Number of subjects: 108
Study 19572930 — intervention group
Group type: COMPARATOR
Intervention: Control group (1.25 mg/ml ropivacaine)
Number of subjects: 108
Study 17868242 — intervention group
Group type: EXPERIMENTAL
Intervention: Certified Safe Farm (CSF) intervention including occupational health screenings, health and wellness screening, education, on-farm safety reviews, and performance incentives.
Number of subjects: 316
Study 17868242 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (no intervention).
Number of subjects: 316
Study 17868242 — intervention group
Group type: EXPERIMENTAL
Intervention: Certified Safe Farm (CSF) intervention.
Number of subjects: 316
Study 17868242 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention cohort (safest farms scoring in the highest tertile).
Number of subjects: 316
Study 17868242 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention cohort (least safe farms scoring in the lowest tertile).
Number of subjects: 316
Study 16868976 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide (CIC) 160 microg/day
Number of subjects: 556
Study 16868976 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 176 microg/day
Number of subjects: 556
Study 12534315 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 10 mg/day
Number of subjects: 75
Study 12534315 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/day
Number of subjects: 75
Study 10649617 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐MPL and QS21 with SBAS‐2
Number of subjects: 30
Study 10649617 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐MPL and QS21 with SBAS‐1
Number of subjects: 30
Study 10649617 — intervention group
Group type: EXPERIMENTAL
Intervention: Alum
Number of subjects: 30
Study 10649617 — intervention group
Group type: EXPERIMENTAL
Intervention: SBAS‐2 with rgp120W61D
Number of subjects: 30
Study 10649617 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 8783388 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist D‐Trp6‐LHRH (Decapeptyl) 3.2 mg for 12 days
Number of subjects: 19
Study 8783388 — intervention group
Group type: COMPARATOR
Intervention: Human menopausal gonadotropin (Pergonal) for 11 days
Number of subjects: 19
Study 1902404 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heparin therapy (n = 99)
Number of subjects: 241
Study 1902404 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (300 mg/day) and dipyridamole (300 mg/day) (n = 103)
Number of subjects: 241
Study 1902404 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heparin therapy
Number of subjects: 241
Study 1902404 — intervention group
Group type: COMPARATOR
Intervention: Aspirin and dipyridamole
Number of subjects: 241
Study 6353879 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 20 mg t.i.d.
Number of subjects: 31
Study 6353879 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg t.i.d.
Number of subjects: 31
Study 6353879 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 60 mg t.i.d.
Number of subjects: 31
Study 6353879 — intervention group
Group type: COMPARATOR
Intervention: Conventional drugs (previous treatment)
Number of subjects: 31
Study 31023380 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate catheter drainage (within 24 h)
Number of subjects: 104
Study 31023380 — intervention group
Group type: COMPARATOR
Intervention: Postponed catheter drainage (current standard care)
Number of subjects: 104
Study 30032443 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynophilus® (Lcr regenerans®) immediate release capsules administered daily for 21 days
Number of subjects: 0
Study 30032443 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynophilus® slow release muco-adhesive tablets administered every 3, 4, or 5 days for 21 days
Number of subjects: 0
Study 30032443 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynophilus® slow release muco-adhesive tablets (administered every 3 or 4 days)
Number of subjects: 0
Study 27769190 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-faceted intervention including clinical audits, training of personnel, and decision-support reminders via text messages.
Number of subjects: 22
Study 27769190 — intervention group
Group type: COMPARATOR
Intervention: Control group (11 hospitals) with no intervention applied.
Number of subjects: 22
Study 25154525 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted health intervention
Number of subjects: 573
Study 21948211 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted perioperative intravenous fluid regimen
Number of subjects: 161
Study 21948211 — intervention group
Group type: COMPARATOR
Intervention: Standard perioperative intravenous fluid regimen
Number of subjects: 161
Study 21948211 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 161
Study 19584979 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg/day for 12 weeks
Number of subjects: 264
Study 19584979 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 264
Study 17594052 — intervention group
Group type: EXPERIMENTAL
Intervention: High hernia sac ligation and excision (group A, n = 238)
Number of subjects: 477
Study 17594052 — intervention group
Group type: COMPARATOR
Intervention: No high hernia sac ligation and excision (group B, n = 239)
Number of subjects: 477
Study 16324298 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane at 1.0 MAC
Number of subjects: 60
Study 16324298 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane at 1.5 MAC
Number of subjects: 60
Study 16324298 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane at 1.5 MAC
Number of subjects: 60
Study 16324298 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane at 0.75 MAC
Number of subjects: 60
Study 16324298 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane at 0.75 MAC
Number of subjects: 60
Study 16324298 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane at 0.75 MAC
Number of subjects: 60
Study 16324298 — intervention group
Group type: EXPERIMENTAL
Intervention: All three anesthetics at 1.0 MAC
Number of subjects: 60
Study 16324298 — intervention group
Group type: EXPERIMENTAL
Intervention: All three anesthetics
Number of subjects: 60
Study 12048365 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard HIV prevention services including access to free condoms, risk-reduction counseling, and STI therapy
Number of subjects: 0
Study 12048365 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrollment in clinical trials offering standard HIV prevention services
Number of subjects: 0
Study 10459399 — intervention group
Group type: EXPERIMENTAL
Intervention: Full (102-g) 15-amino acid drink
Number of subjects: 24
Study 10459399 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarter-strength (25 g) 15-amino acid drink
Number of subjects: 24
Study 10459399 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 24
Study 8665996 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine oral treatment for 8 weeks
Number of subjects: 0
Study 8665996 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine treatment
Number of subjects: 0
Study 8665996 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine clearance (CL)
Number of subjects: 0
Study 1970957 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (0.25 to 2 mg/70 kg)
Number of subjects: 32
Study 1970957 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam (0.5 to 4 mg/70 kg)
Number of subjects: 32
Study 1970957 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (1.5 to 12 mg/70 kg)
Number of subjects: 32
Study 1970957 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (4 to 32 mg/70 kg)
Number of subjects: 32
Study 1970957 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.1, 0.3 and 0.9 mg/70 kg)
Number of subjects: 32
Study 7004273 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.05 mg/kg)
Number of subjects: 61
Study 7004273 — intervention group
Group type: EXPERIMENTAL
Intervention: d-tubocurarine (0.05 mg/kg)
Number of subjects: 61
Study 7004273 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 61
Study 31705448 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 124
Study 31705448 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS)
Number of subjects: 124
Study 31705448 — intervention group
Group type: COMPARATOR
Intervention: Sham EA
Number of subjects: 124